NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Silo Pharma, Inc. (SILO) Stock Analysis

Silo Pharma, Inc. (SILO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SILO

$1.20

$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SILO with… →

SILO Key Statistics

As of Oct 21, 2026
Trading
Open
$1.19
Previous Close
$1.20
Day's Range
1.18–1.23
52-Week Range
1.10–10.43
Volume
7.19K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.91
Valuation
Market Cap
$2.46M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
45.56
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.26
Financials (FY)
Revenue (FY)
$72.10K+0.00%
Net Income (FY)
−$4.23M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.05M
1-Year Return
−86.09%
Dividend and dates
Avg Volume
96.69K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SILO closed at $1.20, −86.09% over 1 year.

Silo Pharma, Inc. (SILO) has a market capitalization of $2.46M.

In fiscal 2025, SILO reported revenue of $72.10K.

SILO Stock Return by Calendar Year

Silo Pharma, Inc. (SILO) return since Jan 2021: what $10,000 became

1 year
$10,000 $1,391
−86.09%
5 years
$10,000 $80
−99.20%
Since Jan 2021
$10,000 $46
−99.54%

If you had invested $10,000 in Silo Pharma, Inc. (SILO) at the close on January 8, 2021, the earliest close on record here, it would have been worth $46 at the close on October 21, 2026: −99.54% in total, −60.62% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−76.47%
2025−61.80%
2024−38.19%
2023−57.14%
2022−53.01%
2021−59.14%

As of October 21, 2026.

SILO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$72.10K−$4.23M−5,863.5%
2024$72.10K−$4.39M−6,092.6%
2023$72.10K−$3.70M−5,132.6%
2022$72.10K−$3.91M−5,420.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$72.10K$27.81K−$4.28M−$4.23M−5,863.5%
2024$72.10K$66.26K−$4.71M−$4.39M−6,092.6%
2023$72.10K$66.26K−$3.86M−$3.70M−5,132.6%
2022$72.10K$66.26K−$3.65M−$3.91M−5,420.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SILO Valuation vs Biotechnology Median

Median of 608 stocks
MetricSILOBiotechnology medianvs median
P/S ratio45.5613.303.4x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Silo Pharma, Inc. (SILO) is capitalised at $2.46M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 3.

The 52-week range on file runs from $1.10 to $10.43. SILO last closed at $1.20 on October 21, 2026. The close was unchanged from the previous session. The latest close sits 9.09% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $72.10K. Against the prior fiscal year total of $72.10K, that is a change of 0.00%. The same year closed with a net loss of $4.23M. Earnings per share on a trailing basis come to −4.26.

Across the 4 fiscal years on file, revenue moves from $72.10K in 2022 to $72.10K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 45.56 times revenue. On price-to-sales that is 3.4 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −86.09%. Across 5 years the annualized return works out at −61.93%. The reported beta is 0.91. Daily returns over the trailing 5 years annualize to a volatility of 1,871.46%.

Growth & Income

No dividend is on file for SILO.

Across the complete calendar years on file, 2024 returned −38.19% and 2025 returned −61.80%. Of the 5 complete calendar years on file, 0 finished higher. So far in 2026 the total return is −76.47%.

Peer Comparison

Silo Pharma, Inc. (SILO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Silo Pharma, Inc. SILO $2.46M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Silo Pharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Silo Pharma, Inc.

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Visit website →